NeuroOne Bets on Drug Delivery and Global Expansion, but Cash Is Running Short
The maker of brain ablation devices sees a larger opportunity in intracranial drug delivery, backed by a landmark FDA reversal, while manufacturing bottlenecks strain near-term growth.
NMTC · Earnings Call · 2026-08-13
A Micro-Cap in Transition
NeuroOne Medical Technologies (NASDAQ:NMTC) reported fiscal Q3 2026 results that show a company at a critical crossroads. Product revenue for its OneRF Brain Ablation System grew 16% year-over-year to $2.0 million, but the quarter also revealed a growing manufacturing backlog that forced the company to trim its full-year revenue outlook. The stock has been hit hard, down 54% over the past 90 days, reflecting investor skepticism about the company's ability to scale operations while burning through cash. Yet beneath these near-term pressures lies a clearer strategic pivot: the company is positioning itself as a key enabler of brain-delivered therapies, a space that just received a major regulatory boost.
StereoCED: Betting on a Wave of Brain-Delivered Therapies
The most compelling narrative emerging from the call is the progress of the drug delivery system, now branded StereoCED. Management highlighted the FDA's decision to allow uniQure's AMT-130 to move toward accelerated approval for Huntington's disease—a decision that validates the market for direct-to-brain drug delivery. Chief Business Officer David Wambecke called it a "major inflection point" for the field. He emphasized that current procedures are resource-intensive: "Depending on the indication, procedures can range from 8 to 12 hours in the operating room and rely entirely on intraoperative MRI guidance." StereoCED is designed to streamline that workflow by using existing neurosurgical equipment and enabling simultaneous multi-trajectory delivery.
If approved, AMT-130 could become the first commercially approved blockbuster therapy delivered directly into the brain.
The company is moving quickly: StereoCED is expected to be ready for human investigational studies by the end of September, with animal research underway. Collaborations with the University of Minnesota (epilepsy) and Mayo Clinic (diffuse midline glioma) are scheduled to begin this month, and the company hopes to book its first device sale to a pharmaceutical company later this year. This is a significant expansion from earlier quarters, where drug delivery was still in the design phase.
International Expansion and Manufacturing Constraints
Another milestone is the receipt of ISO 13485 certification, which is the key to entering international markets. Management noted that Zimmer Biomet will handle some geographies, while NeuroOne will seek independent distributors for others. This was a goal throughout 2026, and its achievement "paves the way for international revenue growth," as CEO David Rosa said. As stated in May: "Yes, the initial plan will be to enter international markets with Zimmer." “Yes, the initial plan will be to enter international markets with Zimmer.” — David Rosa, Chief Executive Officer · 2026-05-12
However, the near-term challenge is supply. The company is working to qualify a second manufacturing site to relieve lead times that can stretch up to six months. Rosa admitted: “We are working closely with our suppliers to expedite manufacturing in order to address any remaining backlog by the end of the fourth calendar quarter of 2026.” — David Rosa, Chief Executive Officer · 2026-08-13 The backlog is a direct result of shifting product demands from Zimmer, and the company is balancing the need to prioritize its largest customer against opportunities in trigeminal neuralgia and other lines.
The company is also expanding its trigeminal neuralgia franchise with independent distributors. In December, Rosa noted: “Yes. So both of those cases were back to back.” — David Rosa, Chief Executive Officer · 2025-12-17 Now, the company is planning a broader commercial push, targeting roughly 30 centers and leveraging a short learning curve. When asked about Zimmer's interest in the product, Rosa said “They are definitely interested.” — David Rosa, Chief Executive Officer · 2026-08-13 but the company is moving forward regardless.
Stretched Finances and a Falling Stock
Financial results highlight the strain. Gross margins expanded to 59.9% on favorable product mix, but operating expenses rose as the company invested in R&D and sales infrastructure. Net loss widened to $2.0 million, and cash stood at just $2.0 million at quarter end. The company has been tapping an ATM facility and executed a 1-for-6 reverse split in April to maintain Nasdaq compliance. Cash and cash equivalents dropped to $2.0M as of June 30, 2026, from $6.6M at September 30, 2025. The company has no debt, but the burn rate raises concerns about dilution.
The stock's decline—the recent 90-day return is -53.8% per the tape—suggests the market is pricing in significant execution risk. Yet management remains optimistic, citing the potential for the drug delivery platform to be transformational. The AMT-130 milestone and distribution partner opportunities provide tangible catalysts, but the company must prove it can execute operationally. For investors, the risk-reward is stark: the stock has lost over 97% of its value since its peak, and today's report does little to reverse that trend, though the drug delivery opportunity remains a wild card.